Facility History

SynCo Bio Partners - GMP Facility

  • 1988 - Cetus Corporation, Emeryville, CA, US establishes its European headquarters, EuroCetus B.V. in Amsterdam, the Netherlands.

  • 1990-1991 - EuroCetus facility licensed for production and release of ProLeukin (IL-2) for Europe and rest of world, except US and Japan.
  • 1992 – Chiron Corporation acquires Cetus Corporation. Eurocetus B.V. becomes Chiron B.V.
  • 1996 – Facility licensed for commercial production of Pertussis vaccine.
  • 1997 – Facility licensed by WHO for commercial production of Meningitis A polysaccharides.
  • 1997-1999 – Facility licensed by UK, MCA and Italian Health Branch for Meningitis C polysaccharide and CRM197 carrier protein for conjugated vaccine Menjugate®.
  • 2000 – Facility acquired by Dr William J. Rutter. SynCo Bio Partners B.V. established.
  • 2001 – Facility licensed by EMA and Health Canada for Meningitis C polysaccharides and CRM197 carrier protein for Menjugate® production.
  • 2004 – Installation of new air handling systems completed for all of its facilities.
  • 2005 – Installation of new aseptic filling machine in its Class A zone, allowing larger batches sizes and expansion of filling ranges.
  • 2005 – Expansion of GMP facilities to allow production of a wider range of protein, vaccine and live biotherapeutic products.
  • 2006 – Facility licensed by Korean FDA for commercial production.
  • 2008 – Expansion of process development capabilities to enable a greater range of projects to be completed.
  • 2009 – Facility licensed by ANVISA for commercial production.
  • 2011 – Expansion of the Class A zone of its aseptic filling facility successfully completed, allowing SynCo to support new product launches in the US and the rest of the world.

About Us